DK2563362T3 - Cyclopropyldicarboxamider og analoger heraf, der udviser anticancer og antiproliferativ aktivitet - Google Patents

Cyclopropyldicarboxamider og analoger heraf, der udviser anticancer og antiproliferativ aktivitet

Info

Publication number
DK2563362T3
DK2563362T3 DK11719421.7T DK11719421T DK2563362T3 DK 2563362 T3 DK2563362 T3 DK 2563362T3 DK 11719421 T DK11719421 T DK 11719421T DK 2563362 T3 DK2563362 T3 DK 2563362T3
Authority
DK
Denmark
Prior art keywords
analogues
antiproliferative activity
exhibiting anticancer
dicarboxamides
cyclopropyl
Prior art date
Application number
DK11719421.7T
Other languages
Danish (da)
English (en)
Inventor
Daniel L Flynn
Michael D Kaufman
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Application granted granted Critical
Publication of DK2563362T3 publication Critical patent/DK2563362T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK11719421.7T 2010-04-29 2011-04-29 Cyclopropyldicarboxamider og analoger heraf, der udviser anticancer og antiproliferativ aktivitet DK2563362T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32954810P 2010-04-29 2010-04-29
PCT/US2011/034556 WO2011137342A1 (en) 2010-04-29 2011-04-29 Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites

Publications (1)

Publication Number Publication Date
DK2563362T3 true DK2563362T3 (da) 2014-06-23

Family

ID=44260801

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11719421.7T DK2563362T3 (da) 2010-04-29 2011-04-29 Cyclopropyldicarboxamider og analoger heraf, der udviser anticancer og antiproliferativ aktivitet

Country Status (17)

Country Link
US (5) US20120058985A1 (OSRAM)
EP (1) EP2563362B1 (OSRAM)
JP (1) JP5795630B2 (OSRAM)
KR (1) KR20130109943A (OSRAM)
CN (1) CN103068384B (OSRAM)
AU (1) AU2011245248B2 (OSRAM)
BR (1) BR112012027743A2 (OSRAM)
CA (1) CA2800569A1 (OSRAM)
DK (1) DK2563362T3 (OSRAM)
ES (1) ES2475741T3 (OSRAM)
IL (1) IL222728A0 (OSRAM)
MX (1) MX2012012571A (OSRAM)
PH (1) PH12012502142A1 (OSRAM)
PT (1) PT2563362E (OSRAM)
RU (1) RU2012151012A (OSRAM)
SG (2) SG10201503394PA (OSRAM)
WO (1) WO2011137342A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009308853A1 (en) * 2008-10-29 2010-05-06 Deciphera Pharmaceuticals, Llc Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
US20120058985A1 (en) * 2010-04-29 2012-03-08 Deciphera Pharmaceuticals, Llc Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities
CN102702121B (zh) * 2012-04-06 2016-04-13 浙江工业大学 一种化合物间羟基苯基四嗪二甲酰胺及制备和应用
CN102702120A (zh) * 2012-04-06 2012-10-03 浙江工业大学 一种新化合物邻羟基苯基四嗪二甲酰胺及制备和应用
AU2013259583A1 (en) 2012-05-08 2014-11-13 The Regents Of The University Of California Alpha 7 nicotinic acetylcholine allosteric modulators, their derivatives and uses thereof
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
EP3696276A1 (en) 2013-02-25 2020-08-19 Novartis AG Novel androgen receptor mutation
US9193719B2 (en) * 2013-03-15 2015-11-24 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
US20170079966A1 (en) * 2014-10-14 2017-03-23 Deciphera Pharmaceuticals, Llc Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
EP3206752A1 (en) * 2014-10-14 2017-08-23 Deciphera Pharmaceuticals, LLC Inhibition of trk kinase mediated tumor growth and disease progression
WO2016061231A1 (en) * 2014-10-14 2016-04-21 Deciphera Pharmaceuticals, Llc Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression
TW201808906A (zh) 2016-03-16 2018-03-16 拜耳作物科學股份有限公司 作為殺蟲劑之經取代吡啶化合物
CN106349158B (zh) * 2016-08-03 2020-02-28 杭州市西溪医院 一种c-Met小分子抑制剂、含其的药物组合物及其药学应用
CN107793363B (zh) * 2016-09-06 2021-02-26 上海医药工业研究院 一种取代芳胺基芳杂环类化合物及其作为抗肿瘤药物的应用
CN106831707B (zh) * 2016-12-28 2019-09-20 杭州市西溪医院 作为c-Met激酶抑制剂的苯并杂环类衍生物及其医疗用途
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
CN109988108B (zh) * 2017-12-29 2022-04-29 江苏豪森药业集团有限公司 一种卡博替尼的制备方法
KR102708050B1 (ko) 2018-01-31 2024-09-24 데시페라 파마슈티칼스, 엘엘씨. 비만 세포증의 치료를 위한 병용 요법
WO2019152711A1 (en) 2018-01-31 2019-08-08 Diciphera Pharmaceuticals Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
SMT202500389T1 (it) 2018-12-28 2025-11-10 Deciphera Pharmaceuticals Llc Inibitori di csf1r per l'uso nel trattamento di tumori tenosinoviali a cellule giganti
PE20220592A1 (es) 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos
HUE065486T2 (hu) 2019-05-10 2024-05-28 Deciphera Pharmaceuticals Llc Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
CA3143489A1 (en) 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
CN115243681B (zh) 2019-12-30 2024-08-16 德西费拉制药有限责任公司 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物
JP2023549540A (ja) 2020-11-18 2023-11-27 デシフェラ・ファーマシューティカルズ，エルエルシー Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法
KR20240133793A (ko) 2021-12-09 2024-09-04 데시페라 파마슈티칼스, 엘엘씨. Raf 키나아제 억제제 및 그 사용 방법
CN114394940B (zh) * 2022-01-26 2024-01-16 武汉工程大学 一种环丙基-1,1二酰胺类化合物及其制备方法和应用
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
US20250205161A1 (en) 2023-12-08 2025-06-26 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538097A (en) * 2004-02-27 2005-12-01 Eisai Co Ltd Novel pyridine derivative and pyrimidine derivative
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
ES2424651T3 (es) 2005-08-24 2013-10-07 Eisai R&D Management Co., Ltd. Nuevo derivado de piridina y derivado de pirimidina (3)
JP2009526761A (ja) 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
JP5190365B2 (ja) 2006-08-23 2013-04-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 フェノキシピリジン誘導体の塩またはその結晶およびそれらの製造方法
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
WO2008046216A1 (en) 2006-10-18 2008-04-24 Methylgene, Inc. Kinase inhibitors and uses thereof
KR20090090365A (ko) 2007-02-23 2009-08-25 에자이 알앤드디 매니지먼트 가부시키가이샤 Ｈｇｆｒ 유전자 증폭 세포주에 대하여 우수한 세포 증식 억제 효과 및 항종양 효과를 나타내는 피리딘 유도체 또는 피리미딘 유도체
JP2010538094A (ja) 2007-09-06 2010-12-09 アレイ バイオファーマ、インコーポレイテッド チロシンキナーゼ阻害剤としてのピラゾロピリジン類
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
JP2009203226A (ja) * 2008-01-31 2009-09-10 Eisai R & D Management Co Ltd ピリジン誘導体およびピリミジン誘導体を含有するレセプターチロシンキナーゼ阻害剤
US20100311972A1 (en) 2008-02-18 2010-12-09 Mitsuo Nagai Method for producing phenoxypyridine derivative
TW201035017A (en) * 2008-09-26 2010-10-01 Smithkline Beecham Corp Preparation of a quinolinyloxydiphenylcyclopropanedicarboxamide
AU2009308853A1 (en) * 2008-10-29 2010-05-06 Deciphera Pharmaceuticals, Llc Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
WO2010064300A1 (ja) 2008-12-02 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 食道癌治療用組成物
JP2010178651A (ja) 2009-02-04 2010-08-19 Eisai R & D Management Co Ltd Ｈｇｆｒ阻害物質の作用検定方法
US20120058985A1 (en) * 2010-04-29 2012-03-08 Deciphera Pharmaceuticals, Llc Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activities

Also Published As

Publication number Publication date
PH12012502142A1 (en) 2017-04-21
AU2011245248A1 (en) 2012-12-20
US20140194405A1 (en) 2014-07-10
MX2012012571A (es) 2013-04-05
SG10201503394PA (en) 2015-06-29
CN103068384B (zh) 2015-03-11
US20120322834A1 (en) 2012-12-20
AU2011245248B2 (en) 2016-01-07
RU2012151012A (ru) 2014-06-10
US20150218130A1 (en) 2015-08-06
US20120252849A1 (en) 2012-10-04
JP2013525458A (ja) 2013-06-20
ES2475741T3 (es) 2014-07-11
IL222728A0 (en) 2012-12-31
PT2563362E (pt) 2014-07-11
US20120058985A1 (en) 2012-03-08
BR112012027743A2 (pt) 2017-03-14
EP2563362A1 (en) 2013-03-06
HK1184392A1 (zh) 2014-01-24
CN103068384A (zh) 2013-04-24
WO2011137342A1 (en) 2011-11-03
EP2563362B1 (en) 2014-03-12
US8637672B2 (en) 2014-01-28
CA2800569A1 (en) 2011-11-03
JP5795630B2 (ja) 2015-10-14
SG185073A1 (en) 2012-12-28
KR20130109943A (ko) 2013-10-08

Similar Documents

Publication Publication Date Title
DK2563362T3 (da) Cyclopropyldicarboxamider og analoger heraf, der udviser anticancer og antiproliferativ aktivitet
IL257693B (en) Fungicidal compositions
DK2640197T3 (da) Sammensætninger omfattende rebaudiosid a, rebaudiosid b og rebaudiosid d
BR112015002738A2 (pt) composto , e , composição farmacêutica
EP2968286A4 (en) 2-AMINOPYRIMIDIN-6-ONE AND ANALOGUE WITH ANTIBODY AND ANTIPROLIFERATIVE EFFECT
GB201421740D0 (en) Noble metal-molecular sieve catalysts
DK2841429T3 (da) Tetrazolinonforbindelser og anvendelse deraf som pesticider
DK3660033T3 (da) Langtidsvirkende compstatinanaloger og tilhørende sammensætninger og fremgangsmåder
EP2814501A4 (en) MELANOCORTINANALOGA WITH INCREASED EFFECTIVENESS AND TRANSPORTATION OF THEREOF
DK2822704T3 (da) Gas-bibeholdende overfladeafdækning, indretning og anvendelse
DK3597644T3 (da) Kationiske aminlipider og anvendelser deraf
BR112013006293A2 (pt) arilpirrolidinas pesticidas
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
BR112018005754A2 (pt) benzamidas substituídas por isoxazolina e análogos como inseticidas.
DK2745849T3 (da) Polydeoxyribonukleotidsammensætning og anvendelser deraf
DK2895163T3 (da) Sammensætninger der omfatter peg og ascorbat
DK2819974T3 (da) Gødningsmiddel, anvendelse deraf og fremstillingsfremgangsmåde
FR2969640B1 (fr) Poudre ignifuge, fongicide et parasiticide
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
DK2807160T3 (da) Antifibrotiske forbindelser og anvendelser deraf
HRP20190529T1 (hr) Kombinirana bačva od nehrđajućeg čelika i drva
DK2914111T3 (da) Sammensætning omfattende chitosan og et fungicid
DK2943460T3 (da) 6-chlor-3-(phenyl-d5)-inden-1-on og anvendelse deraf
DK2849798T3 (da) Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder
BR112016011430A2 (pt) agentes anticâncer e preparação dos mesmos.